RecruitingNCT05923970

Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?

Is a Third Dose of Measles-mumps-rubella-(Varicella) Vaccine (MMR(V)) Vaccine Beneficial for the Adult Population in Alberta?


Sponsor

University of Alberta

Enrollment

200 participants

Start Date

Nov 9, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The current recommendation for a full course of measles-mumps-rubella-(varicella) vaccine (MMR(V)) is two doses. The problem is, many individuals within the vaccinated cohort show antibody levels that are below the level considered to be protective, even after two doses of vaccine. Because of these waning antibody levels, it is currently unknown whether highly vaccinated populations are protected from infection against measles, mumps, rubella, or varicella should they be exposed to any of these viruses. The uncertainty of a woman's immune status is partly due to the type of testing that is used to indicate protection. While immunity to viral infection requires both a humoral and a cell mediated immune (CMI) response, only humoral (antibody) responses are measured routinely in the laboratory. This study will examine CMI responses and the role of a third dose of vaccine for previously vaccinated women whose antibody levels are below the cut off. This study will not administer vaccine, but rather will include women who have received a third dose of vaccination through routine health care follow up in the study cohort.


Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria1

  • Women who are pregnant and have undergone routine prenatal screening for rubella antibodies.

Exclusion Criteria1

  • Women younger than 18 years of age

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTSerology for antibody levels - Baseline

Measurement of rubella IgG antibody levels at baseline

DIAGNOSTIC_TESTSerology to assess cell mediated immune (CMI) response - Baseline

Assessment of cell mediated immune (CMI) response to measles, mumps, rubella, and varicella at baseline.

DIAGNOSTIC_TESTSerology for antibody levels - Post third dose of MMR vaccine

Measurement of rubella IgG antibody levels post third dose of MMR vaccine

DIAGNOSTIC_TESTSerology to assess CMI - Post third dose of MMR vaccine

Assessment of cell mediated response (CMI) to measles, mumps, rubella, and varicella post third dose of MMR vaccine.


Locations(1)

University of Alberta

Edmonton, Alberta, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05923970


Related Trials